Close menu




MORPHOSYS AG O.N.

Photo credits: pixabay.com

Commented by Stefan Feulner on January 10th, 2022 | 11:56 CET

Steinhoff, Almonty Industries, MorphoSys - Closer and closer to the goal

  • tungsten

Will the crisis-ridden international retail group Steinhoff have a happy ending after all? Now that the settlement is likely to be successfully put to bed at the end of January, the highly indebted company's survival is at stake, and it is now striving to gold-plate its well-performing subsidiaries. At Almonty Industries, on the other hand, the signs are pointing to growth. The mega project in South Korea will make the Company one of the most important players in the production of raw materials for the energy transition, with significant upside potential.

Read

Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET

Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?

  • Gold

At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.

Read

Commented by André Will-Laudien on December 23rd, 2021 | 14:19 CET

MorphoSys, NanoRepro, Barsele Minerals, Agnico Eagle - Dramatic turnaround as early as 2022!

  • Gold

After pronounced upswing phases, active market participants often look for the supposedly lagging stocks. This investment strategy sometimes works out, but in most cases, it does not. After all, there are solid reasons why a stock does not participate in the upswing phase on the stock market: poor figures, gloomy prospects or scandals. The reasons why shares fall can be complex, and in most cases, the ownership structure is also an obstacle. But when company stories take a turn for the better, the movements in the share price are noticeable. We provide some ideas for the year 2022.

Read

Commented by Armin Schulz on December 13th, 2021 | 10:18 CET

Barrick Gold, Tembo Gold, MorphoSys - With which merger will 2022 start?

  • Gold

The record in the volume of corporate takeovers had existed for 13 years. According to M&A experts, in 2021, it was broken as early as October. There has never been such a high volume of mergers as this year. A total of USD 5.3 trillion was spent on takeovers. Often, the offers were far above the current market price, such as the takeover of Zooplus, where US investors put EUR 2.8 billion on the table and paid about a 40% premium over the stock market price. Deutsche Bank does not expect acquisitions to decrease in the coming year. Today, we take a closer look at the Barrick Gold and Tembo Gold deal and take a closer look at MorphoSys, another takeover candidate.

Read

Commented by Armin Schulz on November 29th, 2021 | 11:36 CET

MorphoSys, Osino Resources, Bayer - Profits through takeovers

  • Gold

The world's most expensive takeover occurred in Germany when the Vodafone Group acquired the Mannesmann Group for EUR 190 billion in 2000. Initially, Vodafone offered only EUR 100 billion. When a company wants to take over a listed company, it must make a public offer to shareholders. At this point, the buying party is usually already the major shareholder in the takeover target. As a rule, these offers are significantly higher than the current share price in order to make the deal palatable to the shareholders. Payment is made in cash, in shares of the acquiring Company or with a mix of both. Today, we look at three companies that are the subject of takeover rumors.

Read

Commented by Armin Schulz on November 3rd, 2021 | 11:03 CET

MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio

  • Biotechnology

The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.

Read

Commented by Armin Schulz on October 20th, 2021 | 11:04 CEST

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

Commented by Nico Popp on October 15th, 2021 | 10:10 CEST

MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow

  • Healthcare

The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.

Read

Commented by Armin Schulz on September 24th, 2021 | 11:28 CEST

Alibaba, Kainantu Resources, MorphoSys - The turnaround beckons here

  • Gold

A stock that has fallen sharply can offer the chance to make significant gains relatively quickly. Kostolany once said, "What seems cheap can become much cheaper". In other words, one should be wary of reaching for the falling knife. The shares that you have on your watch list as turnaround candidates should be monitored as closely as possible in order to strike at the right moment. The first thing to do after a stock crash is to wait for it to bottom out. To do this, one observes the Company's earnings position. In addition, the Company's story should fit, and entry should be sought using chart technology. Then nothing stands in the way of more considerable price gains. Today, we look at three companies that could be on the verge of a turnaround.

Read

Commented by Carsten Mainitz on September 20th, 2021 | 11:05 CEST

wallstreet:online, Commerzbank, MorphoSys - Things are looking up again!

  • Investments

The stock market environment remains positive. High inflation coupled with low interest rates makes stocks the right investment vehicle. If you are looking for stocks that are noticeably behind the course highs of the last 12 months, you should take a closer look at the following somewhat different companies. Who is ahead at the end of the year?

Read